Pancreatic ductal adenocarcinom a (PDAC), frequently detected at advanced stages, has a 5-year survival rate of 12%. Metastases are common, including hepatic metastasis, which is particularly lethal due to the liver’s immune-tolerant environment and rich blood supply that facilitate tumor growth.
Neuroendocrine prostate cancer (NEPC) is the most aggressive form of prostate cancer, responsible for up to 20% of therapy-resistant cases and associated with rapid disease progression. It is characterized by a loss of typical androgen receptor signaling, conferring antiandrogen therapy resistance, and abnormal expression of neuroendocrine markers, along with small cell morphology.
Hanmi Holdings Co. Ltd. has reported novel skeletal derivatives acting as HER2 mutant inhibitors and thus reported to be useful or the treatment of cancer.
Work at Laekna Therapeutics Shanghai Co. Ltd. has led to the identification of new bicyclic heteroaromatic compounds acting as Myt1 kinase (PKMYT1) inhibitors potentially useful for the treatment of cancer.
Evolveimmune Therapeutics Inc. has announced a translational research collaboration with Memorial Sloan Kettering Cancer Center (MSK) to investigate the expression of a new tumor target – UL binding protein 2 (ULBP2) – in muscle-invasive bladder cancer.
Impact Therapeutics Inc. has synthesized poly(ADP-ribose) polymerase 1 (PARP-1; ARTD1) inhibitors reported to be useful for the treatment of neurologic cancer.
Newave Pharmaceutical LLC has disclosed GTPase KRAS (mutant) inhibitors reported to be useful for the treatment of cancer, autoimmune disease and inflammatory disorders.
In mammals, the fibroblast growth factor (FGF)-FGF receptor (FGFR) interactions control many physiological processes during development and life. Impaired FGFR signaling has been associated with different pathologies, including growth disorders, degenerative diseases and cancer. Thus, targeting FGFR signaling can offer significant therapeutic advantage in these conditions.
RSS
